Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 sept. 2024 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on September 10, 2024, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference
10 sept. 2024 16h01 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present at the 2024 Cantor Global Healthcare Conference on...
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
05 sept. 2024 17h34 HE
|
Travere Therapeutics, Inc.
Travere Therapeutics announced that the U.S. FDA has granted full approval to FILSPARI® (sparsentan) to treat IgA nephropathy.
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024
22 août 2024 16h30 HE
|
Travere Therapeutics, Inc.
Travere today announced that it will present two posters in classical homocystinuria (HCU) at the SSIEM annual symposium.
Travere Therapeutics to Present at Upcoming Investor Conferences
06 août 2024 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in August:...
Travere Therapeutics Reports Second Quarter 2024 Financial Results
01 août 2024 16h01 HE
|
Travere Therapeutics, Inc.
Received 521 new patient start forms (PSFs) for FILSPARI® (sparsentan) in the quarter representing the sixth consecutive quarter of PSF growth; Total of 2,484 PSFs received since launch Net product...
Travere Therapeutics to Report Second Quarter 2024 Financial Results
25 juil. 2024 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced it will report second quarter 2024 financial results on Thursday, August 1, 2024, after the...
Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
08 juil. 2024 16h30 HE
|
Travere Therapeutics, Inc.
Travere Therapeutics management will present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference on Monday, July 15, 2024, at 11:30 a.m. ET.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 juin 2024 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on June 10, 2024, the Compensation Committee of its Board of Directors granted inducement...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
15 mai 2024 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2024, the Compensation Committee of its Board of Directors granted inducement...